On June 6, 2016, during the annual meeting of the American Society of Clinical Oncology (ASCO), Vice President Joe Biden unveiled the Genomic Data Commons (GDC) project.
On June 6, 2016, during the annual meeting of the American Society of Clinical Oncology (ASCO), Vice President Joe Biden unveiled the Genomic Data Commons (GDC) project. The goal of the project is to facilitate sharing of genomic and clinical data and promote advances in personalized cancer treatment. The project, which will be funded by the National Cancer Institute, will have an operations center at the University of Chicago.
Biden noted that there is urgency in finding cures for other diseases, such as Ebola, and that this type of urgency is what is needed in the fight against cancer. He also asked for help in supporting cancer research, early detection, and access to treatment. Biden stated that he hoped that by sharing data, more progress against cancer can be made, noting that “no single oncologist can find the answer on his or her own.” For more on the vice-president’s speech, click here.
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.
2 Commerce Drive
Cranbury, NJ 08512